CONCLUDE 试验的结论有多可靠?
本文评述 CONCLUDE 试验:1609 例 2 型糖尿病患者随机接受德谷胰岛素 U200 或甘精胰岛素 U300,维持期 HbA1c 改善相似,总体低血糖发生率(主要终点)无显著差异,夜间症状性和严重低血糖(次要终点)德谷 U200 较低。作者认为结果不能视为确凿,因主要终点未达到、次要终点分析仅为探索性,且研究设计因血糖仪可靠性问题而修改。
要点
- CONCLUDE 试验中德谷胰岛素 U200 与甘精胰岛素 U300 的总体低血糖发生率(主要终点)无显著差异。
- 夜间症状性和严重低血糖(次要终点)德谷 U200 低于甘精 U300,但主要终点未达到,次要分析仅为探索性。
- 作者强调临床中应监测患者所用血糖仪的可靠性,血糖仪精度不足或使用不当可抵消新胰岛素的微小优势。
核心结论
- CONCLUDE 试验结果虽受临床医生关注,但不能视为确凿结论。
- 主要终点未达到,次要终点分析仅为探索性。
- 即使假设德谷胰岛素在降低低血糖风险上优于甘精胰岛素,其机制仍不明确。
研究设计与样本
- CONCLUDE 试验将 1609 例 2 型糖尿病患者随机分配至德谷胰岛素 200 U/ml(德谷 U200)或甘精胰岛素 300 U/ml(甘精 U300)组。
主要发现
- 维持期两组 HbA1c 改善程度相似。
- 总体低血糖发生率(主要终点)两组无显著差异。
- 夜间症状性低血糖和严重低血糖(次要终点)发生率德谷 U200 低于甘精 U300。
临床怎么用
- 作者认为,CONCLUDE 试验提示临床中需要监测糖尿病患者用于调整胰岛素剂量的血糖仪的可靠性。
- 作者认为,血糖仪精度不足或使用不当可轻易抵消新胰岛素在血糖控制和低血糖风险方面的微小优势。
局限性
- 主要终点未达到,次要终点分析仅为探索性。
- 即使假设德谷胰岛素在降低低血糖风险上优于甘精胰岛素,其机制仍不明确,且因方法学问题难以评估药代动力学和药效学的潜在差异。
- 研究设计因初始所用血糖仪缺乏可靠性(尤其在低血糖范围)而必须修改,不能排除这些修改对试验后续实施的潜在影响。
- 与 BRIGHT 试验(唯一其他头对头研究)的比较因主要终点(HbA1c 降低 vs 低血糖风险降低)、研究人群(胰岛素经治 vs 胰岛素初治)和伴随降糖药物不同而变得复杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of basal insulin analogues has reduced the risk of hypoglycaemia in insulin-treated individuals with type 2 diabetes. Insulin degludec and insulin glargine 300 U/ml (glargine U300) represent an evolution of basal insulin analogues, both of them reducing the risk of hypoglycaemia as compared with that associated with glargine U100. However, whether degludec and glargine U300 are equivalent with respect to glycaemic control and risk of hypoglycaemia remains to be fully ascertained. In the CONCLUDE trial, 1609 individuals with type 2 diabetes were randomised to either degludec 200 U/ml (degludec U200) or glargine U300. In this issue of Diabetologia (https://doi.org/10.1007/s00125-019-05080-9) the investigators report that during the maintenance period, HbA1c improved to a similar extent in the two groups with no significant difference in the rate of overall hypoglycaemia (the primary endpoint of the study), while rates of nocturnal symptomatic and severe hypoglycaemia (secondary endpoints) were lower with degludec U200 than with glargine U300. These results, although of great interest to the clinician, need to be carefully interpreted as they cannot be considered as conclusive. First, the primary endpoint was not met and, therefore, analyses of secondary endpoints remain exploratory. Even assuming that degludec is superior to glargine in reducing the risk of hypoglycaemia, the mechanism(s) accounting for such an advantage remain elusive and potential differences in pharmacokinetics and pharmacodynamics difficult to appreciate because of methodological issues. The study design had to be amended because of lack of reliability of the glucometers initially used in the trial, particularly in the low blood glucose ranges, so the potential implications of these changes in the subsequent conduct of the trial cannot be excluded. Finally, comparison with the BRIGHT trial, the only other available head-to-head study, is complicated by differences between the two studies in the primary endpoint (HbA1c reduction vs reduction of the risk of hypoglycaemia), study population (insulin-experienced vs insulin-naive) and concomitant glucose-lowering medications. In spite of all this, CONCLUDE teaches us an important lesson regarding the need, particularly in the clinical setting, to monitor the reliability of the glucometers the diabetic individual uses to adjust his/her insulin dose. Insufficient precision or inappropriate use of the glucometer can easily offset any minute advantage a new insulin can offer with respect to glycaemic control and risk of hypoglycaemia.
引用
- Del Prato S. How conclusive is the CONCLUDE trial? Diabetologia. 2020. PMID: 31950229. doi:10.1007/s00125-020-05086-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。